KN026

Phase 3Small molecule

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

KN026 is one of 85 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

HER2-Positive Breast CancerActive, not recruiting

Breast CancerPhase 3

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2/Phase 3

Active, not recruiting

HER2-Positive Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

KN026

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

4 2

Halaven

Eisai

Preclinical

38 3

Tykerb

GSK

Preclinical

80 4

Avastin

BBio-Thera Solutions

Preclinical

153 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 6

Prolia

Amgen

Preclinical

14 7

Lexiscan

Astellas

Preclinical

1 8

Voltaren

Novartis

Preclinical

1 9

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 10

Recentin

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Locally Advanced

NCT06023758

Phase 2Not yet recruiting

Colorectal Cancer

NCT05985707

Q4 2027

Phase 3Active, not recruiting

HER2-Positive Breast Cancer

NCT06747338

Q4 2029

Phase 2Not yet recruiting

Gastric Cancer

NCT06998771

Q4 2032

Phase 2/3Not yet recruiting

Gastric Cancer

NCT07332533

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Unknown status·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT04881929·30 enrolled

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07441460·1,800 enrolled

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Unknown status·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT04165993·68 enrolled

Show 1 more trial

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Terminated·JJiangsu Alphamab Biopharmaceuticals Co., Ltd··NCT04778982·4 enrolled

Gastric Cancer4 trials

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06998771·153 enrolled

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Unknown status·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1·NCT03847168·22 enrolled

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT07332533·490 enrolled

Show 1 more trial

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Completed·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1·NCT03619681·63 enrolled

Locally Advanced1 trial

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Recruiting·PPeking University·Phase 2·NCT06023758·18 enrolled

Colorectal Cancer1 trial

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT05985707·80 enrolled

Gastric/Gastroesophageal Junction Cancer1 trial

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Completed·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT03925974·45 enrolled

2 more indications

HER2-Positive Solid Tumor1 trial

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

Completed·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT04521179·102 enrolled

HER2-positive Breast Cancer1 trial

A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.

Active, not recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06747338·520 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for KN026. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KN026 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KN026. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Alphamab Biopharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu Alphamab Biopharmaceuticals Co., Ltd

KN026

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2029

Q4 2032

Trials by Indication[1]

Breast Cancer4 trials

Gastric Cancer4 trials

Locally Advanced1 trial

Colorectal Cancer1 trial

Gastric/Gastroesophageal Junction Cancer1 trial

HER2-Positive Solid Tumor1 trial

HER2-positive Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News